Search results
Chronic Lymphocytic Leukemia: Slow-Appearing Symptoms
Verywell Health via Yahoo News· 9 months agoNew therapies are transforming treatment Halfpoint Images / Getty Images Medically reviewed by...
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
Benzinga via Yahoo Finance· 1 year agoThe FDA has approved BeiGene Ltd's (NASDAQ: BGNE) Bruton's tyrosine kinase inhibitor (BTKi) Brukinsa...
BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins
Investor's Business Daily· 2 years agoBeiGene stock catapulted higher Wednesday after the company's leukemia treatment beat out a...
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Zacks via Yahoo Finance· 3 weeks agoRoche Holding AG RHHBY announced that the late-stage study evaluating its marketed drug, Columvi...
BeiGene's Brukinsa Shows Superior Progression-Free Survival Versus JNJ's Treatment
Benzinga via Yahoo Finance· 2 years agoBeiGene Limited (NASDAQ: BGNE) announced topline data from the Phase 3 ALPINE trial of Brukinsa...
Bristol Myers' CAR T Cell Therapy Shows Deep, Durable Efficacy In Blood Cancer Patients
Benzinga via Yahoo Finance· 11 months agoBristol Myers Squibb Co (NYSE: BMY) announced the first disclosure of results from the primary...
What Is Bone Marrow Cancer?
Health via Yahoo News· 4 months agoBone marrow cancer is a group of cancers that develop in the blood cells of your bone marrow. The bone marrow is the spongey material inside the bones...
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Zacks via Yahoo Finance· 1 month agoIt was a busy week for the biotech sector with lots of study data readouts and regulatory approvals....
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 months agoBeiGene BGNE is expected to report its fourth-quarter 2023 results soon. BeiGene currently markets...
AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica
Zacks via Yahoo Finance· 1 year agoAbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two...
